Register Login
Register to leave comments
  • News bot Jan. 29, 2026, 7:56 p.m.

    📋 Aeglea BioTherapeutics Inc (was renamed to Spyre Therapeutics (SYRE)) (AGLE) - Clinical Trial Update

    Filing Date: 2026-01-12

    Accepted: 2026-01-12 09:00:09

    Event Type: Clinical Trial Update

    Event Details:

    Aeglea BioTherapeutics Inc (was renamed to Spyre Therapeutics (SYRE)) (AGLE) Announces Clinical Trial Update Aeglea BioTherapeutics Inc (was renamed to Spyre Therapeutics (SYRE)) (AGLE) provided an update on its clinical development programs. Clinical Development Highlights:
    • Drug Program: trial
    • Collaboration: Kate Tansey Chevlen
    • Updated Timeline: September 30, 2025
      • expected in 4Q 2026
      • targeting α4ß7, TL1A, and IL-23. For more information, please visit http://spyre.com. Forward-Looking Statements Certain statements in this press release, other than purely historical information, may constitute “forward-looking statements” within the meaning of the federal securities laws, including for purposes of the safe harbor provisions under the United States Private Securities Litigation Reform Act of 1995

    🔬 Clinical Development Pipeline (Aeglea BioTherapeutics Inc (was renamed to Spyre Therapeutics (SYRE))):

    Product Type Development Stage Therapeutic Area Source
    SPY001 DRUG Phase PHASE2 Ulcerative Colitis ClinicalTrials.gov
    SPY003 DRUG Phase PHASE2 Ulcerative Colitis ClinicalTrials.gov
    Placebo OTHER Phase PHASE2 Ulcerative Colitis ClinicalTrials.gov
    SPY002 DRUG Phase PHASE2 Ulcerative Colitis ClinicalTrials.gov
    SPY002-072 DRUG Phase PHASE2 Rheumatoid Arthritis ClinicalTrials.gov
    A2B543 BIOLOGICAL Phase PHASE1 Solid Tumor, Adult ClinicalTrials.gov
    A2B694 BIOLOGICAL Phase PHASE1 Solid Tumor, Adult ClinicalTrials.gov
    TDM-105795 topical vehicle solution DRUG Phase PHASE2 Alopecia, Androgenetic ClinicalTrials.gov
    TDM-105795, 0.02% DRUG Phase PHASE2 Alopecia, Androgenetic ClinicalTrials.gov
    TDM-105795, 0.0025% DRUG Phase PHASE2 Alopecia, Androgenetic ClinicalTrials.gov
    Placecbo DRUG Phase PHASE2 Restless Leg Syndrome ClinicalTrials.gov
    BRC-002 DRUG Phase PHASE2 Restless Leg Syndrome ClinicalTrials.gov
    Apheresis OTHER Preclinical Solid Tumor, Adult ClinicalTrials.gov
    KN5001 BIOLOGICAL Phase EARLY_PHASE1 Pulmonary Nodules, Solitary ClinicalTrials.gov
    Standard of care OTHER Phase PHASE3 Venous Leg Ulcer ClinicalTrials.gov
    TR987 0.1% gel + Standard of Care DRUG Phase PHASE3 Venous Leg Ulcer ClinicalTrials.gov
    Co-ArgI-PEG modified human arginase I DRUG Phase PHASE2 Acute Myeloid Leukemia ClinicalTrials.gov
    AEB1102 DRUG Phase PHASE1 Arginase I Deficiency ClinicalTrials.gov
    Co-ArgI-PEG DRUG Phase PHASE1 Advanced Cancers ClinicalTrials.gov
    Pembrolizumab DRUG Phase PHASE1 Small-cell Lung Cancer ClinicalTrials.gov
    Pegzilarginase DRUG Phase PHASE1 Small-cell Lung Cancer ClinicalTrials.gov
    Pegtarviliase SC DRUG Phase PHASE1 Homocystinuria Due to Cystathionine Beta-Synthase Deficiency ClinicalTrials.gov
    Pegtarviliase IV DRUG Phase PHASE1 Homocystinuria Due to Cystathionine Beta-Synthase Deficiency ClinicalTrials.gov
    SPY001-001 DRUG Phase PHASE1 Healthy ClinicalTrials.gov
    SPY002-091 DRUG Phase PHASE1 Healthy ClinicalTrials.gov
    SPY003-207 DRUG Phase PHASE1 Healthy ClinicalTrials.gov

    💼 Business Developments:

    • Partnership
    • Acquisition: Not available
    • Licensing: Not available
    • Regulatory Approval: Not available
    • Executive Changes: Not available

    Structured Data:

    • Company Name: Aeglea BioTherapeutics Inc (was renamed to Spyre Therapeutics (SYRE))
    • Ticker Symbol: AGLE

Search

News categories